Cryoport's CRYOGENE will provide Moffitt with
state-of-the-art biorepository services
TAMPA,
Fla. and NASHVILLE,
Tenn., Jan. 14, 2025 /PRNewswire/ -- Moffitt
Cancer Center, a leading National Cancer Institute-designated
comprehensive cancer center, through its wholly owned subsidiary
Speros FL, a 775-acre global innovation life sciences campus, and
Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain
solutions for the life sciences industry, today announced a
strategic collaboration that will provide CRYOGENE's
state-of-the-art biorepository services to Speros in Pasco County, Florida. Cryoport's CRYOGENE
business unit is a leading biorepository for the life sciences
industry that is focused on the secure storage of biological
specimens and associated services.
"Our goal is to make Speros the cell and gene therapy capital of
the world," said Patrick Hwu, M.D.,
president and CEO of Moffitt. "With the addition of CRYOGENE, we
will accelerate discovery by igniting collaborations and
partnerships across disciplines to bring new therapies to patients
faster and save more lives. This collaboration builds upon
Moffitt's longstanding partnership with Cryoport's CRYOGENE and
serves as an initial step in transforming our campus into a global
epicenter of innovation."
"Having CRYOGENE's facility with a seasoned team located
directly on the Speros campus and at Moffitt's research facility
provides top-level research and biotech companies with the critical
tools and infrastructure to immediately operate more effectively,"
said Marshall Griswold, CEO of
CRYOGENE. "We all share a common goal to save and improve patients'
lives, and our team is ready and eager to assist Speros and Moffitt
in fulfilling this mission."
The addition of CRYOGENE's biostorage facility will lay the
foundation for Moffitt's Speros campus as a global epicenter for
patient treatment and research in cell and gene therapies,
immunotherapies, radiopharmaceuticals, proton therapies and other
expanding technologies and treatment pathways. This facility will
be included in the initial phase of the development of Speros and
is located adjacent to Moffitt's 250,000-square-foot Discovery
& Innovation Center for research.
Jerrell Shelton, CEO of Cryoport,
added, "We are honored to be partnering with Moffitt's Speros
campus to support the needs of research and cancer patients
receiving medical care at this world class life sciences campus and
cancer center. Through our collaboration, Cryoport's CRYOGENE will
provide cutting-edge biostorage technologies and logistics services
to support patients' treatments as well as the invaluable medical
and biopharmaceutical research taking place at Moffitt to
accelerate scientific discovery and save lives today and
tomorrow."
Biorepositories play a crucial role in the development and
storage of cell and gene therapies, an industry projected to reach
over $97 billion by 2033 with a
compound annual growth rate of 18.3% from 2024 to 2033. CRYOGENE's
optimized storage techniques and strict quality control will enable
reliable and scalable production and preservation of cells that
will accelerate advancements in adoptive cell therapies. This is
key to decentralizing manufacturing, reducing the turnaround time
and bringing lifesaving treatments to patients more quickly.
The facility will enhance collaboration across Moffitt's
expanding health system while also supporting emerging blood
sciences and organ and tissue biobanking protocols. The
biorepository will provide streamlined access to critical research
and clinical activities, along with essential capabilities for
distributing research and treatment materials.
"Bringing a biorepository industry leader like Cryoport to our
emerging life sciences campus is a foundational component of Speros
in providing science as a service," said Sabi Singh, Moffitt's Chief Operating Officer.
"Speros will be a place where paradigm-shifting science impacts
human health. This collaboration with Cryoport will drive other
academic, clinical, life sciences, pharmaceutical and research
institutions to join our mission."
Speros' master development plan for its global innovation
life sciences campus spans multiple phases. Speros will expand the
cancer center's global footprint and will serve as a dynamic nexus
for the convergence of biotech and life sciences. In its initial
phases of development, Speros will focus on mission-critical
activities, including cell and gene therapies, artificial
intelligence, biotech, business incubators and accelerators, drug
discovery, bioengineering, metabolism, data science, machine
learning, health care, life sciences, basic research and
complementary amenities. Construction on Moffitt's outpatient and
proton therapy center began in early 2023 and is scheduled for
completion by 2026.
CRYOGENE focuses on the secure storage of biological
material and provides innovative biostorage solutions to the
research, biotech and pharmaceutical industries. With over 25
million samples securely stored and managed under its care,
CRYOGENE provides the highest quality secure sample storage
services available. CRYOGENE has two locations in Houston and San
Antonio, Texas.
About Speros FL
Speros FL's mission is to
unleash collective genius to improve human life. As a global
innovation hub for science, technology and health care, Speros
brings people and resources together to solve complex problems to
advance hope and a healthier future. A mission-driven real estate
venture, Speros realizes this vision by developing a comprehensive
ecosystem of converging industries, including artificial
intelligence, biotech, business incubators and accelerators, cell
and gene therapies, data, health care, life sciences, machine
learning, research and academia, and complementary amenities. For
more information, visit SperosFL.org.
About Moffitt Cancer Center
Moffitt is dedicated
to one lifesaving mission: to contribute to the prevention and cure
of cancer. The Tampa-based
facility is one of only 57 National Cancer
Institute-designated Comprehensive Cancer Centers, a distinction
that recognizes Moffitt's scientific excellence, multidisciplinary
research, and robust training and education. Moffitt's expert
nursing staff is recognized by the American Nurses Credentialing
Center with Magnet® status, its highest distinction. For
more information, call 1-844-495-1371, visit MOFFITT.org, and
follow the momentum on Facebook, X, Instagram
and YouTube.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq:
CYRX), is a global leader in supply chain solutions for cell &
gene therapies that enable manufacturers, contract development
manufacturers (CDMOs), contract research organizations (CROs),
developers, and researchers to carry out their respective business
with certainty. We provide a broad array of supply chain solutions
for the life sciences industry. Through our platform of critical
products and solutions, which include advanced
temperature-controlled packaging, informatics, specialized
bio-logistics services, bio-storage, bio-services, and cryogenic
systems, we are "Enabling the Future of Medicine™" worldwide,
through our innovative systems, compliant procedures, and agile
approach to superior supply chain management.
Its corporate headquarters, located in Nashville, Tennessee, is complimented by over
50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the
Netherlands, Portugal,
Germany, Japan, Australia, India, and China.
For more information, http://www.cryoportinc.com or
follow via LinkedIn at
https://www.linkedin.com/company/cryoportinc or @cryoport on
X, formerly known as Twitter at www.twitter.com/cryoport for
live updates.
Forward-Looking Statements
Statements in this press
release which are not purely historical, including statements
regarding Cryoport's intentions, hopes, beliefs, expectations,
representations, projections, plans or predictions of the future,
are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, those related to
Cryoport's expectations about future benefits of the strategic
collaboration with Moffitt Cancer Center, including the potential
impact on future revenue and revenue streams. It is important
to note that Cryoport's actual results could differ materially from
those in any such forward-looking statements. Factors that could
cause actual results to differ materially include, but are not
limited to, risks and uncertainties associated with the effect of
changing economic and geopolitical conditions, supply chain
constraints, inflationary pressures, the effects of foreign
currency fluctuations, trends in the products markets, variations
in Cryoport's cash flow, market acceptance risks, and technical
development risks. Cryoport's business could be affected by other
factors discussed in Cryoport's SEC reports, including in the "Risk
Factors" section of its most recently filed periodic reports on
Form 10-K and Form 10-Q, as well as in its subsequent filings with
the SEC. The forward-looking statements contained in this press
release speak only as of the date hereof and Cryoport cautions
investors not to place undue reliance on these forward-looking
statements. Except as required by law, Cryoport disclaims any
obligation, and does not undertake to update or revise any
forward-looking statements in this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moffitt-cancer-center-and-cryoport-announce-strategic-collaboration-302350250.html
SOURCE Cryoport, Inc.
